-
Targeting AR and ARv7 in TNBC: EPI-001 Suppresses Metastasis
2026-07-17
This study establishes androgen receptor (AR) and its splice variant ARv7 as key negative prognostic markers in triple-negative breast cancer (TNBC), with their expression linked to poor survival and metastasis. The research demonstrates that inhibition of AR/ARv7, particularly via the N-terminal domain inhibitor EPI-001, disrupts key metastatic and epithelial-mesenchymal transition (EMT) pathways in TNBC models, highlighting a mechanistically distinct therapeutic direction.
-
Structural Insights into ASCH Domain Proteins and ac4C Proce
2026-07-17
Meng et al. provide the first high-resolution structural analysis of ASCH domain-containing proteins, elucidating the substrate specificity and catalytic mechanism of EcYqfB in converting free N4-acetylcytidine to cytidine. These findings refine our understanding of nucleotide processing enzymes and RNA epigenetics, informing the design of future biochemical and structural studies.
-
CAFs-Derived Lactate Drives Oxaliplatin Resistance in CRC vi
2026-07-16
A recent study reveals that lactate produced by cancer-associated fibroblasts (CAFs) promotes oxaliplatin resistance in colorectal cancer (CRC) by inducing ANTXR1 lactylation, which enhances cancer stemness. These insights highlight the tumor microenvironment's role in chemoresistance and suggest new avenues for improving therapeutic strategies.
-
Live-Dead Cell Staining Kit: Optimizing Dual-Fluorescent Cel
2026-07-16
The Live-Dead Cell Staining Kit harnesses Calcein-AM and Propidium Iodide dual staining for precise, reproducible cell viability measurements—outperforming traditional methods in both sensitivity and workflow versatility. Discover best practices, troubleshooting strategies, and translational insights drawn from recent advances in biomaterial research.
-
CTDNEP1-NEP1R1 Interplay Governs ER Lipid Synthesis and Stor
2026-07-15
This study dissects how CTD-nuclear envelope phosphatase 1 (CTDNEP1) depends on its regulatory subunit NEP1R1 for endoplasmic reticulum (ER) membrane synthesis, but not for lipid droplet biogenesis. The findings clarify the molecular framework of lipid homeostasis, revealing context-dependent regulation that may inform future research on organelle adaptation and metabolic disorders.
-
SP2509: Advanced Epigenetic Modulation in AML and Cancer Res
2026-07-15
Explore the mechanistic depth of SP2509, a potent lysine-specific demethylase 1 antagonist, in cancer epigenetics. Discover how its unique actions unlock new avenues for acute myeloid leukemia research and assay optimization.
-
Tariquidar (XR9576): Potent Noncompetitive P-gp Inhibitor Fa
2026-07-14
Tariquidar (XR9576) is a highly potent, noncompetitive inhibitor of P-glycoprotein (P-gp) used to study drug resistance mechanisms. It blocks P-gp-mediated efflux at nanomolar concentrations, increases intracellular drug retention, and is effective in challenging microenvironments such as high-viscosity tumors. Supplied by APExBIO, Tariquidar is pivotal for transporter-mediated drug disposition and chemoresistance research.
-
Dimethyloxalylglycine (DMOG): Protocols and Technical Use
2026-07-14
Dimethyloxalylglycine (DMOG) enables researchers to mimic hypoxic signaling by stabilizing HIF-1α under normoxic conditions, supporting studies of oxygen sensing and immune modulation. It should be used strictly for preclinical research workflows and is not suitable for diagnostic or therapeutic applications.
-
Budesonide in Respiratory Disease Research: Applied Workflow
2026-07-13
Budesonide streamlines asthma and airway inflammation models by leveraging its potent anti-inflammatory corticosteroid action and optimized pulmonary permeability. Integrating new biomimetic chromatography insights empowers researchers to elevate protocol precision and result reliability. Explore stepwise workflows, troubleshooting tactics, and comparative advantages for respiratory drug development.
-
Canagliflozin Hemihydrate: Specificity, Selectivity, and Ass
2026-07-13
Explore Canagliflozin hemihydrate as a high-purity SGLT2 inhibitor for advanced glucose metabolism research. This article uniquely dissects compound selectivity, assay design, and recent findings on its non-involvement in mTOR pathways, providing unparalleled guidance for diabetes and metabolic disorder studies.
-
Epidermal Growth Factor (EGF), Human Recombinant: Precision
2026-07-12
Explore the unique mechanistic and experimental insights of recombinant human Epidermal Growth Factor (EGF) in regulating cell migration, mucosal healing, and advanced cell signaling research. This article delves deeply into the latest findings and practical assay implications for scientists using EGF in cutting-edge biomedical studies.
-
Cyanidin Chloride: Translating Antioxidant Mechanisms into S
2026-07-10
Explore how Cyanidin Chloride, an anthocyanin polyphenolic antioxidant from Bilberry, is redefining translational research on oxidative stress and inflammatory skin diseases. This article bridges mechanistic insight with actionable guidance for advanced cell-based workflows, highlighting new evidence on cytokine suppression and skin barrier restoration in a psoriasis model. Strategic recommendations, protocol parameters, and a landscape analysis position APExBIO’s Cyanidin Chloride as a validated, high-purity solution for researchers transitioning from preclinical models to mechanistic discovery.
-
CLCC1 Identified as Host Fusion Mediator in Herpesvirus Egre
2026-07-09
The reference study uncovers CLCC1 as an essential host factor facilitating membrane fusion during herpesvirus nuclear egress, a step critical for viral maturation and release. This mechanistic insight clarifies a previously uncharacterized host-virus interaction, opening avenues for targeted antiviral research and informing immunomodulatory strategies against herpesvirus infections.
-
DAMGO (SKU B6621): Reliable µ-Opioid Agonist for Pain Resear
2026-07-09
This article explores real-world laboratory scenarios where DAMGO (SKU B6621) delivers robust, reproducible results in µ-opioid receptor signaling, antinociceptive assays, and chronic pain research. Evidence-backed protocol tips, critical data interpretation, and vendor selection insights empower researchers to optimize their opioid pharmacology workflows using DAMGO from APExBIO.
-
I-BET151 (GSK1210151A): Beyond BET Inhibition in Cancer Rese
2026-07-08
Explore I-BET151 (GSK1210151A) as a selective BET inhibitor, uncovering new mechanistic depth and practical insights for apoptosis and cell cycle assays in cancer biology. This article goes beyond protocols, connecting cutting-edge reference findings to optimize your research.